美股市场个股详情
YMAB Y-mAbs Therapeutics
- 14.710
- -0.130-0.88%
收盘价 04/26 16:00 (美东)
- 14.850
- +0.140+0.95%
盘后 19:05 (美东)
6.44亿总市值-30020市盈率TTM
15.128最高价14.355最低价18.98万股成交量14.920今开14.840昨收278.20万成交额0.75%换手率亏损市盈率(静)4377.71万总股本20.90052周最高6.38市净率3.73亿流通值4.60052周最低--股息TTM2535.76万流通股55.215历史最高--股息率TTM5.21%振幅2.700历史最低14.657平均价1股每手
关于Y-mAbs Therapeutics公司
Y-mAbs Therapeutics Inc 是一家商业化阶段的生物制药公司。该公司主要从事用于治疗癌症的新型抗体治疗产品的开发和商业化。DANYELZA 是该公司第一个获得 FDA 批准的产品，它是一种重组人源化免疫球蛋白 G，1k 亚型，或称 IgG1k 单克隆抗体或 mAb，靶向神经节苷脂 GD2。
公司介绍
公司代码YMAB
公司名称Y-mAbs Therapeutics
上市日期2018/09/21
发行价格16.00
成立日期2015
CEOMr. Michael Rossi
所属市场纳斯达克
员工数量100
证券类型海外普通股
年结日12-31
公司地址230 Park Avenue,Suite 3350
城市New York
省份纽约州
国家美国
邮编10169-0005
电话1-646-885-8505
董事高管
- 姓名
- 职务
- 年薪
- Michael Rossi
- Director, President and Chief Executive Officer
- --
- Sue Smith
- Senior Vice President and Chief Commercial Officer
- 83.36万
- Joris Wiel Jan Wilms
- Senior Vice President and Chief Operating Officer
- --
- Dr. Torben Lund-Hansen, PhD
- Senior Vice President and Chief Technical Officer
- --
- Dr. Steen Lisby
- Senior Vice President and Chief Scientific Officer
- --
- Bo Kruse
- Executive Vice President, Principal Accounting Officer, Chief Financial Officer, Secretary and Treasurer
- 114.85万
- Vignesh Rajah
- Senior Vice President and Chief Medical Officer
- --
- Thomas Gad
- Vice Chairman of the Board and Chief Business Officer
- 143.57万
- Dr. James I. Healy, M.D.,PhD
- Chairman of the Board
- 22.49万
- Dr. Mary A. Tagliaferri, M.D.
- Director
- --
- Dr. Gerard Ber, PhD
- Independent Director
- 21.76万
- David N. Gill
- Independent Director
- 24.26万
- Johan Wedell-Wedellsborg
- Independent Director
- 22.01万
- Dr. Ashutosh Tyagi, M.D.
- Independent Director
- 22.01万
- Laura J. Hamill
- Independent Director
- 22.53万
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅